A method for separating of at least two transition metals, the method comprising: injecting a feed solution into a chromatography column comprising a chromatographic support media, the feed solution comprising at least two transition metals; eluting the feed from the column in an elution cycle by flowing an eluent through the column, wherein a concentration of the eluent is reduced during the elution cycle prior to elution of at least one of the transition metals.

The solution provides a method for separating a Chinese traditional medicine composition. To explain a pharmacological effect mechanism of a medicine made of two or more components and scientific content in rules of compatibility among components of a compound medicine, systematic researches on the material basis is very necessary. Accordingly, deep researches are done on chemical components of the pharmaceutical composition in the solution, and eight compounds are separated, which are 10-O-(p-hydroxycinnamoyl)-adoxosidic acid, aloe-emodin-8-O-β-D-glucopyranoside, quercitrin, matairesinol-4′-O-glucoside, liquiritin apioside, epi-vogeloside, vogeloside and ethyl caffeate, which provides a new quality control method for the composition in the solution.

A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.

A fractionation method, pure active compounds and derivatives thereof, compositions including the same and methods of treating cancer including administering such compounds, derivatives, compositions or any combination thereof. A fractionation method of a Cyathus striatus CBS 126585 for obtaining at least one of the pure active ingredients Striatal C, Striatal C′ or Striatal D, wherein the fractionation method includes: providing an octadecyl silica gel column; and performing a series of RP-18 preparative chromatography steps using the acetadecyl silica gel column.

This invention relates to an aqueous composition comprising, (a) an ion-exchange resin (IXR) comprising microporous beads having a particle size ranging from about 200 um to about 1000 um; (b) a water soluble surfactant having a molecular weight ranging from about 7,500 to about 15,000 Da; and (c) a buffer component; wherein the pH of the aqueous composition ranges from about 5 to about 8, and a process for isolating chemical contaminants using the aqueous composition.

The present disclosure discusses a method of separating and/or purifying acidic peptides by the use of a mobile phase having a pH greater than or about equal to the isoelectric point of one or more of the metal oxides in the flow path.

Methods for determining the relative abundance of viral capsid components in a sample of viral particles are disclosed. In embodiments, methods for determining the relative abundance of empty capsids, partially-full capsids and full capsids (e.g., containing a heterologous nucleic acid molecule) of adeno-associated virus are disclosed.

Provided is a method of purifying a mixture of Fc-containing bioactive peptides by using an affinity column including an affinity matrix containing a protein A ligand, wherein the mixture of Fc-containing bioactive peptides includes a first Fc-containing bioactive peptide and a second Fc-containing bioactive peptide, and the second Fc-containing bioactive peptide includes at least one more human VH3 domain, compared to the first Fc-containing bioactive peptide. According to the purification method, bioactive peptides having the same or similar structures can be precisely separated to the high level of purity while simplification of the process is achieved.

A membrane-based fluid degassing system is arranged for automated control to a degassing efficiency set point, so that fluid is degassed only as necessary. The control variable may be assigned as the degassing environment, to provide the gas transfer driving force suitable to appropriately degas the fluid. By avoiding unnecessary degassing of the fluid, mobile phase pervaporation through the membrane is minimized.

The present disclosure pertains to methods of separating nucleic acid component compounds from one another. In some embodiments, the methods comprise: (a) loading a sample fluid comprising a plurality of nucleic acid component compounds onto a chromatographic column comprising a zwitterionic stationary phase contained inside the column; (b) flowing a mobile phase through the chromatographic column over a time period thereby forming an eluent in which at least some of the plurality of the nucleic acid component compounds are separated from each other, the mobile phase comprising a polar aprotic solvent, a protic solvent, and a volatile buffer salt, wherein flowing the mobile phase comprises varying a ratio of the protic solvent to the polar aprotic solvent over at least a portion of the time period and varying an ionic strength of the volatile buffer salt over at least a portion of the time period.